黑料网

Microbiome; Organ transplantation; Gut microbiome; Infections; Rejection; Graft-versus-host disease; Immunomodulation; Dysbiosis; Fecal microbiota transplantation; Probiotics

Introduction

The human microbiome, comprising bacteria, fungi, viruses, and other microorganisms, plays a vital role in human physiology, including immune system development, metabolism, and nutrient absorption [1]. Disruptions in the microbiome, termed dysbiosis, have been linked to various diseases, including inflammatory bowel disease, autoimmune disorders, and cancer. In the context of organ transplantation, the microbiome has been increasingly recognized as a key factor influencing post-transplant outcomes [2]. The transplantation process itself, including surgery, immunosuppressive medications, and antibiotic use, can significantly disrupt the recipient's microbiome, creating an environment conducive to complications.

Description

Studies have demonstrated a clear link between gut microbiome dysbiosis and post-transplant infections, particularly in liver and lung transplantation [3]. Dysbiosis can lead to increased intestinal permeability, allowing bacteria and bacterial products to translocate into the bloodstream, triggering systemic inflammation and increasing the risk of infections. Specific bacterial taxa have been associated with increased risk of infections, while others have been linked to protective effects.

The microbiome has also been implicated in influencing the risk of rejection after solid organ transplantation. The gut microbiome can modulate the recipient's immune response, affecting the balance between pro-inflammatory and anti-inflammatory pathways [4]. Specific microbial metabolites, such as short-chain fatty acids (SCFAs), can influence T cell function and differentiation, potentially impacting rejection risk. Studies have shown that specific microbial profiles are associated with increased or decreased risk of rejection in different organ transplants.

In HSCT, the microbiome plays a crucial role in the development of GVHD, a severe complication where donor immune cells attack the recipient's tissues [5]. Dysbiosis in the gut can exacerbate GVHD by promoting inflammation and disrupting immune homeostasis. Specific bacterial taxa have been associated with increased risk of GVHD, while others have been linked to protective effects.

Discussion

The mechanisms by which the microbiome influences transplant outcomes are complex and multifaceted. The gut microbiome can modulate the recipient's immune system through various pathways, including influencing the development and function of immune cells, producing microbial metabolites that affect immune cell activity, and modulating intestinal barrier function [6].

Immunosuppressive medications, while essential for preventing rejection, can significantly disrupt the microbiome, creating a vicious cycle. Understanding the interplay between immunosuppression and the microbiome is crucial for developing strategies to minimize post-transplant complications.

Fecal microbiota transplantation (FMT), the transfer of fecal material from a healthy donor to a recipient, has emerged as a potential therapeutic intervention for restoring gut microbiome diversity and function [7]. FMT has shown promising results in treating *Clostridioides difficile* infection and has also been explored in the context of HSCT to prevent or treat GVHD.

Probiotics and prebiotics, which are non-digestible food ingredients that promote the growth of beneficial bacteria, are other potential strategies for modulating the microbiome [8]. However, further research is needed to determine the optimal use of these interventions in transplant recipients.

The use of antibiotics in the peri-transplant period can have a profound impact on the microbiome. Strategies to minimize antibiotic use and promote antibiotic stewardship are crucial for preserving microbiome diversity and function.

The limited sample sizes and heterogeneity of study populations are some of the limitations in the current research. Further large-scale, well-designed clinical trials are needed to validate existing findings and establish the clinical utility of microbiome-based interventions. The impact of the microbiome on long-term transplant outcomes also requires further investigation [9].

Future research should focus on several key areas. Further investigation into the specific microbial taxa and metabolites that influence transplant outcomes is needed. Developing standardized methods for microbiome analysis and defining healthy microbiome profiles in transplant recipients are also important. Large-scale clinical trials are needed to evaluate the efficacy and safety of microbiome-based interventions, such as FMT, probiotics, and prebiotics, in different transplant settings. Developing personalized microbiome-based therapies based on individual patient characteristics and microbiome profiles is a promising area of research [10].

Conclusion

The microbiome plays a significant role in influencing organ transplantation outcomes, impacting the risk of infections, rejection, and GVHD. Understanding the complex interplay between the microbiome, the immune system, and immunosuppressive medications is crucial for developing strategies to improve transplant success. Microbiome-based interventions, such as FMT, probiotics, and prebiotics, hold promise for modulating the microbiome and improving post-transplant outcomes. Continued research in this area is essential for translating these findings into clinical practice and improving the lives of transplant recipients.

Acknowledgement

None

Conflict of Interest

None

References

1. Khosravi N, Pishavar E, Baradaran B, Oroojalian F, Mokhtarzadeh A, et al. (2022) Stem cell membrane, stem cell-derived exosomes and hybrid stem cell camouflaged nanoparticles: A promising biomimetic nanoplatforms for cancer theranostics. J Control Release 348:706-722.

Indexed at, Google Scholar, Crossref

2. Wu HH, Zhou Y, Tabata Y, Gao JQ (2019) Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic. J Control Release 28: 102-113.

Indexed at, Google Scholar, Crossref

3. Yan K, Zhang J, Yin W, Harding JN, Ma F et al. (2022) Transcriptomic heterogeneity of cultured ADSCs corresponds to embolic risk in the host. IScience 4: 104822.

Indexed at, Google Scholar, Crossref

4. Zhang W, Huang X (2022) Stem cell membrane-camouflaged targeted delivery system in tumor. Mater Today Bio 1: 100377.

Indexed at, Google Scholar, Crossref

5. Li Y, Wu H, Jiang X, Dong Y, Zheng J, et al. (2022) New idea to promote the clinical applications of stem cells or their extracellular vesicles in central nervous system disorders: Combining with intranasal delivery. Acta Pharm Sin B 12: 3215-3232.

Indexed at, Google Scholar, Crossref

6. Ji B, Cai H, Yang Y, Peng F, Song M, et al. (2020) Hybrid membrane camouflaged copper sulfide nanoparticles for photothermal-chemotherapy of hepatocellular carcinoma. Acta Biomater 111: 363-372.

Indexed at, Google Scholar, Crossref

7. Wang M , Xin Y , Cao H , Li W , Hua Y, et al. (2021) Recent advances in mesenchymal stem cell membrane-coated nanoparticles for enhanced drug delivery. Biomater Sci 9:1088-1103.

Indexed at, Google Scholar, Crossref

8. Xia Q, Zhang Y, Li Z, Hou X, Feng N, et al. (2019) Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application. Acta Pharm Sin B 9: 675-689.

Indexed at, Google Scholar, Crossref

9. Shin MJ, Park JY, Lee DH, Khang D (2021) Stem Cell Mimicking Nanoencapsulation for Targeting Arthritis. Int J Nanomedicine 16: 8485-8507.

Indexed at, Google Scholar, Crossref

10. Vasanthan V, Hassanabad AF, Fedak PWM (2021) Commentary: Cell therapy for spinal regeneration-implications for recovery after complex aortic surgery. JTCVS Open 24: 45-46.

Indexed at, Google Scholar, Crossref